Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Key Steps in Precision Treatment: A Detailed Overview of CAR-T Infusion for a Russian Patient at Jiahui in Shanghai
Key Steps in Precision Treatment: A Detailed Overview of CAR-T Infusion for a Russian Patient at Jiahui in Shanghai**
Vladimir Borzenkov, a 68-year-old patient from St. Petersburg, Russia, recently completed the core phase of CAR-T therapy—reinfusion—at Jiahui International Hospital in Shanghai. This crucial step involves reinfusing T-cells, which have been genetically modified to recognize and attack specific cancer cells, back into the patient’s body. For Mr. Vladimir, who has been battling his condition for over five years, this step is particularly significant.
Before the reinfusion, the medical team conducted a comprehensive physical assessment to ensure his body could withstand the procedure. Despite being in his sixties, Vladimir’s determination and desire for a cure helped him overcome any obstacles posed by his age. His journey began in December 2017 with back pain, which progressively worsened over several months. By February 2018, multiple bones, including his spine, sternum, and clavicle, showed signs of deterioration. Although this period seemed like a relentless trial, Vladimir never lost his faith in life. Now, at this critical juncture, he is filled with hope for the future.
For this treatment, Jiahui Hospital utilized FUCASO (Eque-cel), a fully human CAR-T therapy known for its unique low immunogenicity and lasting efficacy, providing therapeutic advantages for the patient. During the reinfusion process, Jiahui Hospital demonstrated advanced capabilities in monitoring and managing adverse reactions. The hospital is equipped with the latest monitoring technology and a highly experienced medical team, ensuring that any potential adverse reactions are promptly identified and managed, thus ensuring the safety and effectiveness of the treatment. This high level of monitoring and detailed attention to the patient’s health made Vladimir’s treatment process not only efficient but also safe.
Through his experience at Jiahui International Hospital, Vladimir witnessed the powerful potential of CAR-T therapy and the significant advantages of FUCASO. He is now filled with hope for the future treatment outcomes. This treatment marks not only a significant milestone in his personal battle against cancer but also showcases Jiahui’s expertise in CAR-T technology and excellent patient care.
#CART #MultipleMyeloma #FUCASOJourney #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART #CancerTreatment
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Latest Breakthrough: Chinese Biotech Company Achieves Milestone with Targeted CT041 CAR-T Therapy in Treating Gastrointestinal Tumors
🌟 Latest Breakthrough: Chinese Biotech Company Achieves Milestone with Targeted CT041 CAR-T Therapy in Treating Gastrointestinal Tumors 🌟
Gastrointestinal Tumor
Chinese biotech company CARsgen Therapeutics unveiled the latest data for its targeted Claudin18.2 autologous CAR-T cell candidate product, CT041, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This therapy is specifically designed for Claudin18.2-positive solid tumors, such as gastric cancer, gastroesophageal junction adenocarcinoma, and pancreatic cancer.
🔬 **About CT041**
CT041 (satricabtagene autoleucel, satri-cel) is a groundbreaking CAR-T cell therapy undergoing multiple clinical trials in both China and the United States. Since 2022, it has received RMAT designation and orphan drug status from the FDA, and PRIME designation from the EMA.
📊 **Clinical Trial Highlights**
Between March 2019 and January 2024, a total of 98 patients participated in the Phase 1 trial of CT041. The trial results indicated:
– **Safety**: The most common adverse events were hematologic toxicities related to lymphocyte depletion, with no dose-limiting toxicities or treatment-related deaths reported.
– **Efficacy**: The overall objective response rate (ORR) was 37.8%, and the disease control rate (DCR) was 75.5%. The median progression-free survival (PFS) was 4.4 months, and the median overall survival (OS) was 8.4 months.
For gastric cancer patients, the results were even more remarkable:
– **ORR**: 57.4%
– **DCR**: 83.0%
– **Median PFS**: 5.8 months
– **Median OS**: 9.7 months
🎯 **Future Outlook**
CT041 has demonstrated promising safety and highly encouraging efficacy in heavily pretreated Claudin18.2-positive advanced gastrointestinal cancer patients. This breakthrough brings new hope and treatment options for patients with gastrointestinal tumors.
Follow us for more updates on the latest medical breakthroughs! 💡🌐
Whatsapp：+8613717959070
Email: doctor.huang@globecancer.com
#MedicalBreakthrough #CancerTreatment #CAR_T #CT041 #GastricCancer #PancreaticCancer #CARsgenTherapeutics #ASCO2024 #MedicalAdvances #CARsgen
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
New Breakthrough! Chinese Medical Team’s Remarkable Results with CLDN18.2 CAR-T Therapy for Pancreatic Cancer!
“New Breakthrough! Chinese Medical Team’s Remarkable Results with CLDN18.2 CAR-T Therapy for Pancreatic Cancer! 🎉”
Pancreatic Cancer
On May 25, 2024, the Journal of Clinical Oncology (JCO) published groundbreaking research by Professor Lin Shen’s team from Peking University Cancer Hospital on the application of CLDN18.2 CAR-T cell therapy for refractory metastatic pancreatic cancer, achieving impressive outcomes!
This study summarized the results of two phase I/Ib prospective clinical trials, involving a total of 24 advanced pancreatic cancer patients. Observations post-treatment revealed partial tumor shrinkage and significant reductions in CA19-9 levels in some patients, indicating a positive response. The research also demonstrated that CLDN18.2 CAR-T therapy not only showed significant efficacy in second- and third-line treatments but also exhibited promising potential in extending patient survival.
Assessment of treatment safety showed that the safety profile of CT041 cell therapy in this study was similar to previous findings, with no predefined dose-limiting toxicities observed. Treatment-related adverse events were mainly manageable, with cytokine release syndrome (CRS) and gastrointestinal adverse events typically mild and alleviated through proactive clinical management.
The results of this study demonstrate the potential and prospects of CLDN18.2 CAR-T cell therapy in CLDN18.2-positive metastatic pancreatic cancer patients. Significant reductions in CA19-9 levels, a disease control rate of 70.8%, and a significant extension of overall survival were observed, with treatment safety effectively controlled.
The publication of these research findings brings new hope for pancreatic cancer patients and provides important references for further research and clinical application of CLDN18.2 CAR-T cell therapy. We look forward to this breakthrough bringing gospel to more patients! 🌟
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#PancreaticCancer #CAR-TTherapy #MedicalBreakthrough
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Ключевой этап точечного лечения: Подробное объяснение афереза CAR-T для российского пациента в Шанхайской Международной больнице Жияхуи
Ключевой этап точечного лечения:
Подробное объяснение афереза CAR-T для российского пациента в Шанхайской Международной больнице Жияхуи
Владимир Борзенков, 68-летний пациент из Санкт-Петербурга, в последнее время прошел важный этап лечения CAR-T в Международной больнице Жияхуи в Шанхае – аферез. Этот процесс включает в себя сбор Т-клеток из организма пациента для дальнейшей генетической модификации и увеличения. Владимир выразил благодарность профессионализму лечебной команды и прозрачности лечебного процесса, что не только сняло его беспокойство, но и увеличило уверенность в успехе лечения. Больница Жияхуи использовала свои передовые устройства и технологии, чтобы обеспечить Владимиру плавный и эффективный опыт афереза, гарантируя высококачественный сбор Т-клеток и заложив прочный фундамент для следующих этапов лечения.
#CART #МножественнаяМиелома #ОдобрениеФУКАСО #Эквесел #БольницаЖияхуи #Шанхай #ВыжившийОтРака #КровяноеРак #Иммунотерапия #ПолностьюЧеловеческийCART
#CART #MultipleMyeloma #FUCASOapproval #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Key Step in Precision Treatment: Detailed Explanation of CAR-T Apheresis for a Russian Patient at Jiahui International Hospital in Shanghai
Title:
Key Step in Precision Treatment: Detailed Explanation of CAR-T Apheresis for a Russian Patient at Jiahui International Hospital in Shanghai
Content:
Vladimir Borzenkov, a 68-year-old Russian patient from Saint Petersburg, recently underwent a crucial step in CAR-T therapy at Jiahui International Hospital in Shanghai – apheresis. This process involves collecting T cells from the patient’s body for further genetic modification and amplification. Vladimir expressed appreciation for the professionalism of the treatment team and the transparency of the treatment process, which not only alleviated his anxiety but also increased confidence in the success of the treatment. Jiahui Hospital utilized its advanced facilities and technology to provide Vladimir with a smooth and efficient apheresis experience, ensuring high-quality collection of T cells and laying a solid foundation for the next steps of treatment.
#CART #MultipleMyeloma #FUCASOapproval #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Exploring CAR-T Therapy: Advantages and Challenges
Exploring CAR-T Therapy: Advantages and Challenges
CAR-T Therapy
CAR-T therapy, as an emerging immunotherapy approach, is gradually attracting attention. Its advantages in the field of cancer treatment bring hope, yet it also faces challenges that need to be overcome.
### Advantages:
**1. Powerful Antitumor Effect:**
CAR-T therapy modifies a patient’s T cells to enhance their ability to attack cancer cells. This customized treatment method can precisely identify and destroy tumor cells, offering new treatment opportunities for patients.
**2. Long-Term Survival:**
CAR-T therapy has a longer survival time, reducing the frequency of treatment for patients, thus reducing the inconvenience and pain associated with treatment, while also providing assurance of sustained efficacy.
**3. Low Side Effects:**
Compared to traditional chemotherapy and radiation therapy, CAR-T therapy has relatively low side effects. This reduces the occurrence of severe systemic toxicity reactions and central toxicity reactions, making patients more tolerable to the treatment process.
**4. Significant Treatment Effects in Blood Cancer:**
CAR-T therapy has achieved remarkable achievements in the field of blood cancer. Whether it’s acute lymphoblastic leukemia or multiple myeloma, it has shown significant efficacy, bringing new vitality to patients.
### Challenges:
**1. Risk of B-Cell Depletion:**
CAR-T therapy may lead to a decrease in the number of B cells in the patient’s body, increasing the risk of infection, requiring close monitoring and management.
**2. Off-Target Effects:**
Although CAR-T therapy is highly specific, there is still a risk of damaging normal cells, necessitating further improvement in treatment precision.
**3. Cytokine Release Syndrome (CRS):**
CAR-T therapy may trigger CRS, leading to severe immune reactions that require timely intervention.
**4. Neurotoxicity:**
Neurological symptoms may occur during treatment, requiring timely identification and management to reduce adverse effects on patients.
**5. High Treatment Costs:**
The production cost of CAR-T therapy is high, limiting its widespread clinical application, necessitating the search for cost-reduction methods to benefit more patients.
Although CAR-T therapy faces some challenges, with the continuous progress of science and technology and the deepening of research, we believe that these issues will gradually be resolved. As an innovative treatment method, CAR-T therapy brings new hope to cancer patients. We look forward to its greater role in the future, bringing better quality of life and treatment outcomes to patients. 🌟
#CAR-Ttherapy #CancerImmunotherapy #MedicalTechnologyInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
🔬✨ Overall Response Rate 50%! Chinese Research Entity’s Solid Tumor CAR-T Hits Colorectal Cancer
🔬✨ Overall Response Rate 50%! Chinese Research Entity’s Solid Tumor CAR-T Hits Colorectal Cancer
Colorectal Cancer
#Solidtumor
In the journey to conquer cancer, a significant breakthrough is stirring! Shanghai Sundise Biotech has successfully developed the first candidate product GCC19CART, based on its independently developed CoupledCAR® platform technology. This innovative autologous #CART therapy product is specifically designed to target solid tumors of recurrent/refractory metastatic colorectal cancer (R/R mCRC). Let’s delve into this milestone achievement together!
#GCC19CART
On April 19, 2022, Shanghai Sundise Biotech announced that its solid tumor CAR-T product GCC19CART had been granted Fast Track designation by the U.S. Food and Drug Administration (#FDA). This news implies that the development of GCC19CART will be accelerated, bringing hope and new treatment options to more colorectal cancer patients.
#NCCN
So, what is recurrent/refractory colorectal cancer? According to the definition by the National Comprehensive Cancer Network (NCCN), it refers to patients who have undergone multiple rounds of conventional treatment without success or have developed metastases, facing extremely limited treatment options. Current statistics show that the survival rate and objective response rate of such patients are extremely low, urgently requiring more effective treatment methods.
#colorectalcancer
GCC19CART has demonstrated significant clinical activity by targeting and eliminating cancer cells expressing the colorectal cancer tumor marker GCC. According to publicly available data, GCC is widely expressed in colorectal cancer and is highly expressed in metastatic colorectal cancer cells, making it an ideal target for treatment. Preliminary clinical trial results indicate that GCC19CART exhibits significant objective response rates and acceptable safety profiles in refractory metastatic colorectal cancer, bringing new hope to patients.
#ORR 50%
A multicenter Phase I dose-escalation clinical trial conducted in China showed that the objective response rate in the medium-dose group (2×106 CAR-T/kg) reached an encouraging 50%. This suggests that GCC19CART may become an important choice for treating recurrent/refractory colorectal cancer, bringing longer survival and better quality of life to patients.
#Hope
Colorectal cancer is a disease that seriously threatens human health, and the successful development and clinical trial results of GCC19CART bring us new hope. Let’s look forward together to the early clinical application of this innovative treatment method, bringing light to more patients in need of help!
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: 137 1795 9070
Email: doctor.huang@globecancer.com
💪💊 #ColorectalCancer #CARTtherapy #MedicalInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China’s First CAR-T Trial: “Pay-for-Performance” Introduced!
China’s First CAR-T Trial: “Pay-for-Performance” Introduced! 
CAR-T
China has taken a groundbreaking step towards pay-for-performance! Fosun Kite announces an exciting initiative: the ¥1.2 million(RMB) #CARTcell therapy will now be paid based on its effectiveness! 
NO CR – Refund
This means that eligible patients using Fosun Kite’s #CARTtherapy, #Axicabtagene Ciloleucel, will undergo effectiveness assessment three months after drug purchase and infusion. If complete remission (CR) is not achieved, patients will receive a refund of up to ¥600,000(RMB)! 
This innovative payment model
is not only China’s first for lymphoma drugs but also the country’s first for bio-innovative drugs! 
is an immunotherapy method that involves genetically modifying a patient’s T cells outside the body to recognize specific tumor targets before reinfusing them to precisely combat #tumors. Currently, five products, including Fosun Kite’s #AxicabtageneCiloleucel, have been approved domestically. 
As a form of immunotherapy, CAR-T cell therapy works by collecting a patient’s T cells and genetically modifying them outside the body to recognize specific tumor targets. These modified T cells are then reintroduced into the patient, enabling precise targeting and attacking of tumors. Currently, there are five approved products domestically, including Axicabtagene Ciloleucel from Fosun Kite, Relmacabtagene Autoleucel from JW Therapeutics, Equecabtagene Autoleucel from IASO Bio, Inaticabtagene Autoleucel from Juventas, and Zevorcabtagene autoleucel from CARsgen.
New Hope
Unlike traditional drugs, CAR-T requires individualized production for each patient, thus incurring higher costs. However, this innovative pay-for-performance model brings new hope to patients! 
“Cure” standards
Fosun Kite’s project leader stated that they will collaborate with clinical experts, health commissions, treatment demonstration centers, and other stakeholders to establish “Cure” standards, objectively assessing lymphoma efficacy. This will provide reliable evaluation criteria for performance-based payment! 
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
The world’s first #CART therapy approved for second-line treatment of multiple myeloma is claimed by a Chinese pharmaceutical company
The world’s first #CART therapy approved for second-line treatment of multiple myeloma is claimed by a Chinese pharmaceutical company
Mutiple myeloma
#Legend Biotech
How to advance #CARTcell therapy to frontline treatment is the goal every CAR-T company strives for. On April 5, 2024, local time, Chinese pharmaceutical company Legend Biotech (LEGN.NS) shared exciting news as the U.S. Food and Drug Administration (#FDA) officially approved #ciltacabtageneautoleucel for treating relapsed or refractory multiple myeloma patients. This significant decision brings new hope to patients who have undergone first-line treatment and developed resistance to standard therapies.
#Ciltacabtagene autoleucel
Ciltacabtagene autoleucel becomes the world’s first CAR-T product approved for second-line treatment! This milestone event paves the way for Legend Biotech to enter the global CAR-T market. What’s even more inspiring is that just the day before, the FDA approved BMS’s CAR-T therapy Abecma for third-line treatment of multiple myeloma. The approval of ciltacabtagene autoleucel signifies the strong competitiveness and innovation capabilities of Chinese pharmaceutical companies in the CAR-T field.
Marketing
As early as February 28, 2022, ciltacabtagene autoleucel was first approved for marketing in the United States for the treatment of relapsed or refractory multiple myeloma in adults. As a pioneer of Chinese original CAR-T cell therapy, the successful market launch of this drug has won new glory for China’s biopharmaceutical industry. Currently, ciltacabtagene autoleucel is marketed in the United States, European Union, and Japan, and is also undergoing regulatory review in China, expected to be marketed domestically soon.
Personalized Immunotherapy
The CEO of Legend Biotech stated that the expanded indication of ciltacabtagene autoleucel is expected to change the treatment landscape of multiple myeloma, providing physicians and patients with a personalized immunotherapy option for early treatment. Multiple myeloma is an incurable and progressive hematologic malignancy, thus urgently requiring innovative treatment options, for which ciltacabtagene autoleucel is designed.
HOPE
The successful approval of ciltacabtagene autoleucel not only brings hope to patients but also outlines a new chapter for the future development of CAR-T therapy. In this hopeful moment, let’s look forward to CAR-T technology bringing health and happiness to more patients in the future!
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
Email: doctor.huang@globecancer.com,
WhatsApp: 137 1795 9070
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
#EBMT Conference Reveals the Best CAR-T Therapy for Multiple Myeloma – Equecabtagene Autoleucel
#EBMT Conference Reveals the Best CAR-T Therapy for Multiple Myeloma – Equecabtagene Autoleucel
Multiple myeloma
Introduction:
In recent years, there has been a breakthrough in the research of #CART therapy for relapsed and refractory #multiplemyeloma (RRMM). This treatment method holds promise to address the challenges of inadequate response depth and short duration of response in #RRMM patients, offering hope for achieving minimal residual disease (#MRD) negativity and functional cure in this population.
Key Findings at EBMT:
The upcoming 50th European Society for Blood and Marrow Transplantation (EBMT) congress is set to unveil abstracts shedding light on the efficacy of targeted #BCMA CAR-T therapies. A recent abstract titled “Indirect Comparison of the Effectiveness of Targeted BCMA CAR-T Products in RRMM (#MAIC)” for the first time reveals efficacy comparisons among four BCMA CAR-T products. The study demonstrates that Equecabtagene Autoleucel outperforms other BCMA CAR-T therapies in terms of overall response rate (#ORR) and complete response (#CR) rate, offering significant hope for RRMM patients.
#Equecabtagene Autoleucel: Pioneering Fully-human BCMA #CARTTherapy:
#EquecabtageneAutoleucel, the world’s first approved Fully-human BCMA CAR-T therapy, received priority review and approval in China on June 30, 2023. The MAIC analysis underscores its favorable efficacy. This article provides a systematic analysis of the efficacy data of Equecabtagene Autoleucel in the Chinese population over the past two years, as revealed in the dynamic disclosures at various international academic conferences post-approval.
Efficacy Data Highlights:
– In the #FUMANBA-1 Ib/II clinical study conducted in China, the sCR/CR rate reached an impressive 82.4% among RRMM patients.
– The latest data presented at the 2023 International Myeloma Society (#IMS) conference demonstrated a MRD negativity rate of 97.8% among the enrolled patients, indicating substantial tumor burden reduction.
– With a median follow-up of 18.07 months, long-term efficacy data showcased remarkable outcomes, including a median PFS not yet reached, 12-month continuous MRD negativity rate of 81.7%, and 12-month PFS rate of 85.5%.
Differentiating Factors:
– Equecabtagene Autoleucel exhibited shorter median time to response (#TTR) compared to other CAR-T therapies, indicating faster onset of action.
– The dissociation kinetics of Equecabtagene Autoleucel closely resemble those of natural T cells, facilitating efficient activation, killing, and proliferation within the body.
– Its rapid dissociation pattern minimizes CAR-T cell exhaustion, ensuring sustained efficacy and long-term surveillance against tumor recurrence.
Conclusion:
The emergence of Equecabtagene Autoleucel heralds a new era in CAR-T therapy for RRMM, offering superior efficacy and durable responses. With its unique structural advantages and promising clinical data, Equecabtagene Autoleucel stands as a beacon of hope for RRMM patients worldwide, bringing them closer to achieving disease control and improved quality of life.
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
Email: doctor.huang@globecancer.com
WhatsApp: +8613717959070
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Approval of #Liver Cancer CAR-T Product Targeting #GPC3 Propels China’s CAR-T Therapy Forward
Approval of #Liver Cancer CAR-T Product Targeting #GPC3 Propels China’s CAR-T Therapy Forward
Liver cancer, CAR-T
CT011
On January 15, 2024, #CARsgen Pharmaceuticals announced that its autologous #CARTcell candidate product #CT011, targeting Glypican-3 (GPC3), has been approved for clinical use in China. It is intended for the treatment of GPC3-positive stage IIIa hepatocellular carcinoma patients at risk of recurrence after surgical resection.
Glypican-3 (GPC3)
Glypican-3 (GPC3)plays a crucial role in regulating cell growth and differentiation and is closely associated with the occurrence and progression of liver cancer. GPC3 is expressed in reproductive system tumors such as hepatocellular carcinoma, ovarian clear cell carcinoma, and yolk sac tumors. Its expression rate in hepatocellular carcinoma reaches 74.8%, while it is virtually absent in normal liver tissue, making it an ideal new target for #livercancer #CARTtherapy.
Promising Target
Due to its tumor specificity, GPC3 is considered a promising target for cancer immunotherapy. Higher expression of GPC3 in hepatocellular carcinoma is associated with poorer prognosis.
Frontiers in Immunology
In August 2022, a Chinese medical team published a long-term survival case report of treating advanced hepatocellular carcinoma with CT011 in the journal “#FrontiersinImmunology.” The study reported complete remission (#CR) and long-term survival in a patient with advanced hepatocellular carcinoma after receiving GPC3 CAR-T cell therapy in combination with the multi-target kinase inhibitor sorafenib.
Results showed good tolerance to CT011 combined with sorafenib treatment. The patient achieved partial remission (PR) from the third month onwards and attained complete remission at the 12th month after the first CT011 infusion. The tumor did not progress for over 36 months, maintaining complete remission status for over 24 months after the first infusion.
Cancer Communications
On October 12, 2023, CARsgen Pharmaceuticals announced the clinical efficacy of its independently developed CAR-T cell therapy targeting GPC3 in two patients with advanced hepatocellular carcinoma (HCC). The clinical trial results were published in “#CancerCommunications.” Both patients had inferior prognostic outcomes upon enrollment, with one having inferior vena cava tumor thrombus and the other having retroperitoneal lymph node metastasis.
In the clinical trial, one patient received local treatment for intrahepatic recurrent tumors and inferior vena cava tumor thrombus (microwave ablation and gamma knife) before receiving CAR-T cell therapy targeting GPC3. Six months later, AFP (alpha-fetoprotein) levels normalized, and imaging revealed no active tumors. The other patient underwent local treatment (microwave ablation and gamma knife) for controlling intrahepatic tumors, inferior vena cava tumor thrombus, and peritoneal lymph node metastases while receiving CAR-T cell therapy.
Encouragingly, both patients showed significant efficacy after combined local treatment and CAR-T cell infusion, maintaining tumor-free status during long-term follow-up, with both individuals being tumor-free for over 7 years. Throughout the follow-up period, both patients only received oral antiviral therapy for hepatitis B and did not undergo any other cancer treatment.
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈
🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈
cancer fight
🌟Mr. C from California, USA
It’s yet another heartening piece of news as Mr. C from California, USA, undergoes cross-border treatment at Jiangsu Province People’s Hospital in China, successfully overcoming multiple myeloma and embracing a new lease on life! After meticulous treatment spanning one and a half months, Mr. C, accompanied by his loved ones, has made a successful recovery and been discharged from the hospital, becoming the first American patient to be successfully treated with CAR-T cell therapy for multiple myeloma in China.
🌞New treatment method
Mr. C, a 56-year-old American who is passionate about sports, discovered he had multiple myeloma after sustaining sports-related injuries. Despite enduring several unsuccessful treatment attempts, he refused to give up and began seeking treatment opportunities worldwide. However, the exorbitant cost of treating multiple myeloma in the USA deterred him. After comparing prices and data of CAR-T therapy for multiple myeloma between the USA and China, he ultimately decided to explore the new treatment method at Jiangsu Province People’s Hospital.
🌤Upon arriving in China,
Mr. C not only received meticulous care from medical staff but also had the opportunity to explore the scenic beauty of cities such as Nanjing, Suzhou, and Hangzhou, experiencing the unique cultural charm of China. During the CAR-T cell therapy treatment process, Mr. C underwent a life-threatening cytokine storm, but with the emergency intervention of the medical team, he successfully weathered the storm. Today, he has recovered and been discharged from the hospital, though slightly fatigued, he is still filled with hope and gratitude.
🔥Hope and Courage
Although Mr. C’s treatment has concluded, follow-up work will continue, with the medical team maintaining contact with his family doctor to closely monitor treatment effectiveness and subsequent conditions. As medical personnel, they sincerely hope that this treatment will provide Mr. C with more opportunities for survival.
☀️Mr. C also expressed his desire to revisit China, specifically Nanjing, to visit the experts and nurses who treated him, and of course, to continue savoring Chinese cuisine. This journey of treatment across continents not only granted Mr. C a new lease on life but also showcased the unity and dedication of medical personnel from both China and the USA. May this touching story inspire more people and bring forth more hope and courage!
⭐️CAR-T therapy
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
You can send electronic copies or photos of genetic testing reports and diagnostic reports to:
💌: doctor.huang@globecancer.com
📞WhatsApp 137 1795 9070
✨The Medical Department will contact you as soon as receive the reports.
#CARTtherapy #LymphomaTreatment #CompleteRemission #MedicalAdvancements #CancerResearch #CARTProgress #HopeForPatients #SurvivingLymphoma #HealthcareInnovation #PatientStories #CancerCure #CARTSuccess #MedicalBreakthrough #ImprovingOutcomes #LymphomaAwareness #FightAgainstCancer #CARTJourney #MedicalMilestone #LongTermSurvival #BeatingCancer #lymphoma #cancerawareness